Satraplatin

An orally available platinum analog for the treatment of cancer

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous infusion. In addition, their utility is often limited by toxicity, particularly neurotoxicity, ototoxicity and renal toxicity. Satraplatin has preclinical antitumor activity comparable with that of cisplatin and, clinically, has a more manageable side-effect profile. Satraplatin is active in lung, ovarian and prostate cancer, and appears to have good efficacy in combination with radiation for lung and head and neck cancer. Preclinical data suggest it may also be effective for the treatment of certain cisplatin-refractory tumors. A large, randomized Phase III trial is currently evaluating satraplatin in combination with prednisone for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed following prior systemic therapy. Positive results from this trial would support regulatory approval for satraplatin for this indication. The availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities associated with traditional intravenous platinum compounds makes satraplatin an alternative to other platinum agents and a new treatment option in the oncologist's armamentarium.

Original languageEnglish (US)
Pages (from-to)973-982
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume6
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Platinum
Neoplasms
Lung Neoplasms
Head and Neck Neoplasms
Cisplatin
Therapeutics
Prostatic Neoplasms
Platinum Compounds
Prednisone
satraplatin
Intravenous Infusions
Ovarian Neoplasms
Colorectal Neoplasms
Hormones
Radiation
Kidney
Pharmaceutical Preparations

Keywords

  • Cisplatin
  • Head and neck cancer
  • Prostate cancer
  • Radiation
  • Satraplatin

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Satraplatin : An orally available platinum analog for the treatment of cancer. / Choy, Hak.

In: Expert Review of Anticancer Therapy, Vol. 6, No. 7, 07.2006, p. 973-982.

Research output: Contribution to journalArticle

@article{b4f4a11167b346b5bef6197a01c204d0,
title = "Satraplatin: An orally available platinum analog for the treatment of cancer",
abstract = "Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous infusion. In addition, their utility is often limited by toxicity, particularly neurotoxicity, ototoxicity and renal toxicity. Satraplatin has preclinical antitumor activity comparable with that of cisplatin and, clinically, has a more manageable side-effect profile. Satraplatin is active in lung, ovarian and prostate cancer, and appears to have good efficacy in combination with radiation for lung and head and neck cancer. Preclinical data suggest it may also be effective for the treatment of certain cisplatin-refractory tumors. A large, randomized Phase III trial is currently evaluating satraplatin in combination with prednisone for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed following prior systemic therapy. Positive results from this trial would support regulatory approval for satraplatin for this indication. The availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities associated with traditional intravenous platinum compounds makes satraplatin an alternative to other platinum agents and a new treatment option in the oncologist's armamentarium.",
keywords = "Cisplatin, Head and neck cancer, Prostate cancer, Radiation, Satraplatin",
author = "Hak Choy",
year = "2006",
month = "7",
doi = "10.1586/14737140.6.7.973",
language = "English (US)",
volume = "6",
pages = "973--982",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Satraplatin

T2 - An orally available platinum analog for the treatment of cancer

AU - Choy, Hak

PY - 2006/7

Y1 - 2006/7

N2 - Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous infusion. In addition, their utility is often limited by toxicity, particularly neurotoxicity, ototoxicity and renal toxicity. Satraplatin has preclinical antitumor activity comparable with that of cisplatin and, clinically, has a more manageable side-effect profile. Satraplatin is active in lung, ovarian and prostate cancer, and appears to have good efficacy in combination with radiation for lung and head and neck cancer. Preclinical data suggest it may also be effective for the treatment of certain cisplatin-refractory tumors. A large, randomized Phase III trial is currently evaluating satraplatin in combination with prednisone for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed following prior systemic therapy. Positive results from this trial would support regulatory approval for satraplatin for this indication. The availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities associated with traditional intravenous platinum compounds makes satraplatin an alternative to other platinum agents and a new treatment option in the oncologist's armamentarium.

AB - Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous infusion. In addition, their utility is often limited by toxicity, particularly neurotoxicity, ototoxicity and renal toxicity. Satraplatin has preclinical antitumor activity comparable with that of cisplatin and, clinically, has a more manageable side-effect profile. Satraplatin is active in lung, ovarian and prostate cancer, and appears to have good efficacy in combination with radiation for lung and head and neck cancer. Preclinical data suggest it may also be effective for the treatment of certain cisplatin-refractory tumors. A large, randomized Phase III trial is currently evaluating satraplatin in combination with prednisone for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed following prior systemic therapy. Positive results from this trial would support regulatory approval for satraplatin for this indication. The availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities associated with traditional intravenous platinum compounds makes satraplatin an alternative to other platinum agents and a new treatment option in the oncologist's armamentarium.

KW - Cisplatin

KW - Head and neck cancer

KW - Prostate cancer

KW - Radiation

KW - Satraplatin

UR - http://www.scopus.com/inward/record.url?scp=33746407791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746407791&partnerID=8YFLogxK

U2 - 10.1586/14737140.6.7.973

DO - 10.1586/14737140.6.7.973

M3 - Article

VL - 6

SP - 973

EP - 982

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 7

ER -